Integrated analysis of single-cell and bulk RNA sequencing identifies GSTM4 as a tumor suppressor and prognostic biomarker in breast cancer
Open Access
- 3 November 2025
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-22
Abstract
Background Breast cancer (BC) continues to be a predominant cause of cancer-related deaths among women globally, highlighting the complexity of the disease, its propensity for metastasis, and resistance to conventional therapies. The discovery of clinical biomarkers and therapeutic targets is crucial for advancing BC treatment strategies. Methods We conducted a Transcriptome-Wide Association Study (TWAS) and Weighted Gene Co-expression Network Analysis (WGCNA) to pinpoint genes associated with BC, with GSTM4 emerging as a candidate tumor suppressor. To further elucidate GSTM4’s role, we analyzed its mRNA and protein expression using multiple databases. The prognostic significance of GSTM4 was evaluated using KM-Plotter tools, while its epigenetic profile was examined through GSCA. Protein–Protein Interaction (PPI) networks were constructed with GeneMANIA and STRING to explore GSTM4’s functional interactions. The ssGSEA algorithm and TIMER were employed to link GSTM4 with the immune context of BC. Single-cell RNA sequencing from GSE148673 was analyzed to investigate GSTM4’s influence on the tumor immune microenvironment. In vitro experiments were designed to assess GSTM4’s impact on BC cell behavior. Results GSTM4 expression is diminished in BC tissues and is positively linked to better patient outcomes. Epigenetic studies indicate that GSTM4 silencing may partly result from promoter deletion mutation. The PPI network and enrichment analysis are consistent with GSTM4’s multifaceted role in glutathione metabolism, detoxification, antioxidant defense, and oxidoreductase reactions. GSTM4 expression shows a negative correlation with immune checkpoint gene expression and is associated with an enhanced antitumor immune response in BC as well as increased sensitivity to anticancer drugs. Single-cell RNA sequencing analysis suggests a association of GSTM4 with the prevention of epithelial transformation, the mitigation of BC cell malignancy, and the promotion of tumor microenvironment interactions. In vitro studies confirm GSTM4’s inhibitory effects on BC cell proliferation, invasion, and stemness. Conclusion Integrated analyses identify GSTM4 as a potential tumor suppressor and prognostic biomarker in BC, suggesting its promise for advancing therapies.Keywords
Funding Information
- National Natural Science Foundation of China (82303432)
- China Postdoctoral Science Foundation (2020M681116)
This publication has 18 references indexed in Scilit:
- Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trialCell Research, 2023
- 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio) Hexanol Inhibits Proliferation and Induces Apoptosis of Endometriosis by Regulating Glutathione S-Transferase Mu Class 4Reproductive Sciences, 2023
- Gamma-glutamyltransferase 7 suppresses gastric cancer by cooperating with RAB7 to induce mitophagyOncogene, 2022
- Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130JNCI: Journal of the National Cancer Institute, 2021
- Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry womenNature Communications, 2021
- FBXO6-mediated RNASET2 ubiquitination and degradation governs the development of ovarian cancerCell Death & Disease, 2021
- Immunotherapy for early breast cancer: too soon, too superficial, or just right?Annals of Oncology, 2021
- Delineating copy number and clonal substructure in human tumors from single-cell transcriptomesNature Biotechnology, 2021
- The landscape of cancer cell line metabolismNature Medicine, 2019
- A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast CancerCell, 2019